Personalized Cancer Therapy via Genetic Variant Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments often fail to account for individual genetic variations, leading to ineffective therapies and side effects due to a one-size-fits-all approach, as they do not consider the unique genetic or phenotypic makeup of patients.
Innovation Solution
The development of a method that utilizes human genetic variation analysis and rationally-designed sequence selection to tailor medications and diagnostics, focusing on rare but significant genomic variants across diverse populations, enabling personalized treatments by targeting specific polymorphic variants of a Target of Interest (TOI) with anti-TOI ligands.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If a one-size-fits-all medical treatment approach is used, then the treatment can be administered to all patients uniformly, but it leads to ineffective therapies and side effects due to not accounting for individual genetic variations
Solution Approach 1:
The invention segments the patient population based on their genetic variants of the target protein. Instead of treating all patients uniformly, the approach divides them into groups based on whether they possess specific amino acid variants (such as Variant 1 or Variant 2), allowing for tailored treatment strategies that account for individual genetic differences and improve treatment efficacy.
Solution Approach 2:
The invention applies local quality by matching specific treatments to specific genetic subgroups. Patients with Variant 1 receive Treatment A, while patients with Variant 2 receive Treatment B. This ensures that each patient receives a treatment optimized for their specific genetic makeup, thereby improving reliability and reducing side effects.
2Reliability
If personalized medicine approaches are implemented to account for genetic variations, then treatment efficacy is improved, but the complexity of diagnosis and treatment selection increases
Solution Approach 1:
The invention performs preliminary action by conducting genetic testing to identify the patient's specific target protein variant before treatment selection. This advance identification simplifies the subsequent treatment decision-making process, as the genetic profile directly guides which treatment should be administered, reducing the complexity of treatment selection.
Solution Approach 2:
The invention changes the parameter used for treatment selection from general clinical criteria to specific genetic parameters (amino acid variants). By using genetically-based parameters, the system transforms a complex clinical decision-making process into a more straightforward genotype-to-phenotype matching approach.
3Device complexity
If standard medical treatments are used without considering genetic variants, then the treatment protocol remains simple, but medication wastage occurs due to ineffective therapies
Solution Approach 1:
The invention performs preliminary genetic testing to identify which patients are likely to respond to a given treatment. This preliminary action prevents the administration of ineffective medications to patients who would not benefit, thereby reducing medication wastage while maintaining relatively simple treatment protocols based on genetic matching.
Data Source
AI summary
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.